New Data Show Stiolto Respimat Provides Clinically Meaningful Improvements in COPD Health-Related Quality of Life Measure
Boehringer Ingelheim has announced the publication of new data from the Phase IIIb OTEMTO 1&2 trials, which show Stiolto Respimat provided clinically meaningful improvements in SGRQ total score, compared with placebo, in patients with chronic obstructive pulmonary disease (COPD). These data are published online in the journal, Respiratory Medicine.
COPD, which includes chronic bronchitis and emphysema, is a serious but treatable lung disease that can negatively impact a patient's ability to breathe. Along with improving lung function, another major goal of treatment is improving health-related quality of life.
In COPD, health-related quality of life is commonly measured using the SGRQ, a disease-specific patient-reported instrument that evaluates symptoms, activity limitation and the social and emotional impact of the disease. A reduction in SGRQ score represents an improvement, while a reduction of 4 points or more compared with placebo is considered clinically meaningful. In the OTEMTO trials, patients taking Stiolto Respimat reported a reduction in SGRQ total score of 4.67* points compared with placebo.
"In the recent publication of the OTEMTO trials, Stiolto Respimat improved the SGRQ scores by more than 4 points which is considered the minimum clinically important difference for this measure of health-related quality of life among COPD patients," said Gary T. Ferguson, Pulmonary Research Institute of Southeast Michigan, Farmington Hills, Michigan, and study investigator. "These data add to the growing body of evidence for Stiolto Respimat, which has been clinically proven to significantly improve lung function compared to tiotropium Respimat, olodaterol Respimat and placebo, with a similar safety profile."
Data from the OTEMTO studies are included in an sNDA currently under review by the FDA.
Stiolto Respimat was approved in May 2015 for the long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. Stiolto Respimat is not indicated to treat asthma or acute deterioration of COPD.
Related News
-
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva. -
News CPHI Podcast Series: Why we need to consider women in clinical trials
The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population. -
News US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy... -
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. -
News Novel oral Type 1 diabetes drug gains US FDA IND designation
A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment. -
News A Day in the Life of a Vice President in R&D & Engineering
In the Day in the Life of Series, we've already had the chance to get to know a range of people in various roles in the pharma industry. In the latest interview we get a glimpse into the R&D side of things from Jennifer Sorrells, Vice Presiden...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance